Micreos Human Health develops targeted antibacterial products for human health based on its endolysin technology.
In 2013 we introduced the world's first series of endolysin based products for human health. Launched under the Gladskin brand, these products have already helped thousands of people with inflammatory skin conditions such as eczema, rosacea, psoriasis and inflammatory acne. The endolysin Staphefekt SA.100, the active ingredient in these Gladskin products, specifically targets S. aureus, including the resistant MRSA. S. aureus causes the majority of all bacterial skin infections and aggravates many skin conditions. The Gladskin products are prescription-free and are available in Europe and an increasing number of other countries.
Erasmus Medical Centre is currently running a randomised controlled trial with Gladskin Eczema (the 'Maas Trial'), expected to be concluded by the beginning of 2018.
The company's proprietary endolysin XZ.700 is in clinical development for registration as a pharmaceutical product for various different indications. XZ.700 specifically kills S. aureus, now established as a major trigger for flares in eczema. Atopic Dermatitis is the first targeted XZ.700 indication. A combined Phase I/II trial is scheduled to start in 2018. Details on the company's clinical development program are available upon request.
In October 2014 Micreos also introduced Staphefekt XDR.300, a liquid solution against S. aureus including MRSA.
Our pipeline also includes products against intracellular Staph and other bacterial species
|
Latest fact sheets on: |
|
Staphylococcus aureus |
Micreos Staphefekt SA.100 |
 Download |
|
Colonization Infection Continuum |
Micreos Staphefekt SA.100 |
Download |
|
Eczema |
Micreos Staphefekt SA. 100 (Gladskin) |
Download |
|
Rosacea |
Micreos Staphefekt SA.100 (Gladskin) |
Download |
|
Acne |
Micreos Staphefekt SA.100 (Gladskin) |
Download |
|
Folliculitis/Furunculosis |
Micreos Staphefekt SA.100 (Gladskin) |
Download |
Antibiotic Resistant infections kill or infect an ever increasing number of people. Today, in the USA, more people are killed by MRSA than by AIDS.
Most of the bacteria in our gut and on our skin, are beneficial. Antibiotics do not distinguish between these 'good' and certain 'bad' bacteria, they target both. Though this 'broad-spectrum' bacterial killing of antibiotics was originally seen by many as an advantage, nowadays it is understood that it is far better to leave the beneficial bacteria in tact, to help protect our health.
With Micreos' targeted antibacterial endolysin technology, for the first time this has become possible. That is why this technology is set to replace the use of antibiotics in many applications.
Extra benefits:
1) no known adverse events
2) only the targeted bacterial species are killed, including the antibiotic-resistant ones
3) endolysins can be used in combination with other antimicrobials and therapies
For inquiries or partnerships, please contact us at: info@micreos.com